[Corrections] Correction to Lancet Neurol 2019; 18: 145–54
LeWitt PA, Hauser RA, Pahwa R, et al, on behalf of the SPAN-PD Study Investigators. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 2019; 18: 145–54—In this Article, CVT-301 was incorrectly spelled in some instances in the Summary and Results sections. This correction has been made to the online version as of Jan 18, 2019.
Ander nieuws
[Comment] A new step towards targeting tau
Progressive supranuclear palsy is a rare neurodegenerative disease characterised by an axial parkins...
[Review] CSF and blood biomarkers for Parkinson’s disease
In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers are urg...
Parkinson’s disease patient: ‘I can walk… it’s really helped me’
Parkinson's disease patient Gail Jardine can walk more freely after having a spinal implant fit...